Healthcare Realty Trust Inc (HR)·Q1 2025 Earnings Summary

Executive Summary

• Q1 2025 was operationally in line with management’s plan: Normalized FFO/share was $0.39; same-store cash NOI rose 2.3% YoY; and the company reaffirmed 2025 guidance. GAAP EPS was a loss of $(0.13) on continued non-cash items and modest impairments .
• Versus consensus, revenue modestly beat while GAAP EPS was a slight beat; however, NAREIT FFO/share likely missed as analysts modeled ~FFO/share (REIT) near $0.39 vs actual $0.35. Normalized FFO/share of $0.39 matched company cadence (see Estimates Context) .
• Management outlined a focused turnaround: drive 200–300 bps occupancy lift toward “low 90s,” execute portfolio optimization with outright asset sales, deleverage from 6.4x, and attack G&A/property OpEx to expand margins; dividend will be an “output,” not an input, of the plan .
• Balance sheet actions continue: $28M Q1 dispositions, $38M loan repayment in April, revolver capacity ~$1.4B, and repayment of $250M May 2025 notes (post-quarter). Net debt/Adj. EBITDA run-rate at 6.4x; FY25 target 6.0–6.25x .

What Went Well and What Went Wrong

• What Went Well

  • Normalized FFO/share of $0.39, consistent with management’s cadence and FY25 guidance reaffirmation. CFO expects sequential acceleration in same-store NOI and uptick in FFO/FAD in Q2 .
  • Leasing demand robust: 1.45M sf commencements; 370k sf new leases signed; tenant retention improved to 84.8%; leasing spreads +2.3% cash; SNO pipeline >630k sf (~165 bps future occupancy) .
  • Clear strategic direction from new CEO: “only pure-play outpatient medical REIT,” path to low-90s occupancy, asset sales in non-scaled/orphaned markets, deleveraging, and efficiency push to lift NOI margins beyond low-60s .

• What Went Wrong

  • NAREIT FFO/share at $0.35 trails the ~$0.39 consensus (see Estimates Context), reflecting non-cash/other items; GAAP net loss persisted given depreciation and impairments ($12.1M Q1) .
  • Same-store cash NOI growth 2.3% YoY, below FY guide midpoint cadence, due to elevated operating expenses/weather and tougher comps; mgmt expects re-acceleration in remaining quarters .
  • FAD payout still >100%: Q1 FAD $102.2M vs $109.8M dividends/OP dists; mgmt reiterated dividend to be set after strategic/earnings clarity, not before .

Financial Results

Q1 2025 vs Estimates (consensus):

Values with * are from S&P Global consensus (see disclaimer). Primary EPS actual shown as $(0.099) aligns to $(0.13) diluted EPS after share/framework differences; directionally a small beat.*

Same-store/Portfolio detail (cash NOI mix):

Key KPIs:

Drivers/why: Q1 seasonally weaker with ~$0.01 of seasonal expense; same-store growth suppressed by weather-linked OpEx and difficult comp; mgmt expects acceleration from Q2 on leasing and expense normalization .

Guidance Changes

Earnings Call Themes & Trends

Management Commentary

• “Healthcare Realty is the only pure play outpatient medical REIT… our vision is to be the first choice for equity investors… and the landlord of choice for health systems.”
• “Same store occupancy was 89.3%… I believe stabilized occupancy should be in the low 90% area… expect sequential occupancy growth through 2025.”
• “Focus on exiting markets where we have limited scale… sell assets rather than contribute them to our joint ventures… extend tenor of our debt and reduce overall indebtedness.”
• “The dividend will be an output of the strategic plan and not an input.”
• CFO: “Normalized FFO/share was $0.39… Q1 is seasonally our weakest quarter with almost $0.01 of seasonal expenses… expect material acceleration in same-store cash NOI for the remainder of the year.”
• CFO on capital: “Sold four buildings for $28M in Q1… received $38M loan payoff post-quarter… paid down $35M in term loans; repaid $250M notes using revolver, to be reduced with sale proceeds.”

Q&A Highlights

• Strategy timing and priorities: Portfolio optimization and deleveraging “in the very near term” to reflect in 2026 numbers; occupancy path to low-90s likely 2–3 years .
• JV stance: Likes JVs but prioritizing outright sales for optimization; potential JV growth when cost of capital improves .
• Dividend: Trending toward coverage by 2H 2025, but decision awaits full plan; retained cash would be redeployed first to high-return redevelopments .
• Margins: Pursuing OpEx/G&A efficiencies, tech enablement, and local empowerment; “improve NOI margins beyond low-60s” .
• Policy/tenant risk: Monitoring DC policy; Prospect paying; Steward re-leasing now in pipeline; neither prospect nor Steward upside in guide .
• Leverage: “6.4x… that’s just too high”; target somewhere closer to 5–6x over time; near-term focus is creating balance sheet capacity .

Estimates Context

• Q1 2025 revenue beat consensus by $2.0M ($299.0M vs $297.0M). GAAP EPS modestly beat (about $0.003). NAREIT FFO/share likely missed relative to consensus ($0.35 vs ~$0.389), while Normalized FFO/share printed $0.39 consistent with internal cadence (consensus for normalized not tracked) .
• Estimate participation was moderate (Q1: 7 rev, 4 EPS). Given reaffirmed full-year guidance and management’s expectation for accelerating same-store growth and FFO/FAD in Q2, estimate revisions may skew modestly higher on revenue/same-store and lower on NAREIT FFO sensitivity if non-cash drag persists .

S&P Global estimates used: Revenue Consensus Mean, Primary EPS Consensus Mean, FFO / Share (REIT) Consensus Mean, Revenue - # of Estimates, Primary EPS - # of Estimates.*

Key Takeaways for Investors

• Execution in line: Normalized FFO cadence and reaffirmed FY25 guide support a “turnaround while pruning” narrative; near-term catalysts include asset sales and balance sheet de-risking .
• Watch the mix: Expect revenue/NOI momentum from occupancy and SNO conversions in 2H, while NAREIT FFO can remain choppy given non-cash items; mgmt guiding to sequential improvement from Q2 .
• Balance sheet actions are central: Outright sales in non-core/non-scaled markets to fund deleveraging toward 6.0–6.25x in 2025; revolver provides $1.4B capacity as bridge .
• Dividend is a lagging variable: Board reviews coverage as plan clarifies; target to improve coverage through efficiency gains, leasing, and deleveraging before any potential reset .
• Operating setup favorable: Health system demand resilient; leasing interest strong; internal efficiency and local empowerment should support margin expansion over time .
• Risk/upsides: Prospect payments (not assumed) and Steward re-leasing backfill present un-modeled upside; policy risk monitored but seen as manageable with potential outpatient tilt benefits .
• Stock reaction catalysts: Specific asset sale prints (cap rates), clarity on deleveraging trajectory, margin saves quantified, and any dividend coverage milestones could move the shares .

—
*Values retrieved from S&P Global.